0 1000

Cited 6 times in

Effects of 5-alpha reductase inhibitors: new insights on benefits and harms

DC Field Value Language
dc.contributor.author이주용-
dc.contributor.author조강수-
dc.date.accessioned2018-08-28T17:13:58Z-
dc.date.available2018-08-28T17:13:58Z-
dc.date.issued2018-
dc.identifier.issn0963-0643-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162388-
dc.description.abstractPURPOSE OF REVIEW: The use of 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) and other diseases has been proposed and studied. However, the controversy about its benefits and harms for other diseases has persisted. In this review, we will discuss the newly identified effects of 5ARIs based on recently published studies. RECENT FINDINGS: These drugs are currently recommended in clinical guidelines for BPH. However, the reporting of adverse effects, including sexual dysfunction as well as neurologic, endocrine, and cardiovascular effects, have been controversial. There are reports of additional effects of 5ARI in prostate cancer and bladder cancer. Although 5ARIs have been prescribed for the treatment of androgenic alopecia (AGA), postfinasteride syndrome can result, with symptoms that range from sexual dysfunction to muscle atrophy. SUMMARY: Clinical applications of 5ARIs have been established for the treatment of BPH and AGA from a series of randomized controlled trials. The adverse effects of 5ARIs affect only a small proportion of treated patients and can be resolved with discontinued treatment. It will be necessary to establish the mechanism by which 5ARIs elicit these effects through better designed studies.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfCURRENT OPINION IN UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleEffects of 5-alpha reductase inhibitors: new insights on benefits and harms-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Urology-
dc.contributor.googleauthorJoo Yong Lee-
dc.contributor.googleauthorKang Su Cho-
dc.identifier.doi10.1097/mou.0000000000000497-
dc.contributor.localIdA03161-
dc.contributor.localIdA03801-
dc.relation.journalcodeJ03408-
dc.identifier.eissn1473-6586-
dc.identifier.pmid29528971-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00042307-201805000-00012&D=ovft&PDF=y-
dc.contributor.alternativeNameLee, Joo Yong-
dc.contributor.alternativeNameCho, Kang Su-
dc.contributor.affiliatedAuthorLee, Joo Yong-
dc.contributor.affiliatedAuthorCho, Kang Su-
dc.citation.volume28-
dc.citation.number3-
dc.citation.startPage288-
dc.citation.endPage293-
dc.identifier.bibliographicCitationCURRENT OPINION IN UROLOGY, Vol.28(3) : 288-293, 2018-
dc.identifier.rimsid59972-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.